Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins

Clinical and Vaccine Immunology

Volumn 14, Issue 3, 2007, Pages 331-333

  Haynes, Lia M ^a   Miao, Congrong ^a   Harcourt, Jennifer L ^a   Montgomery, Joel M ^b   Mai, Quynh Le ^e   Dryga, Sergey A ^c   Kamrud, Kurt I ^c   Rivers, Bryan ^c   Babcock, Gregory J ^d   Oliver, Jennifer Betts ^b   Comer, James A ^b   Reynolds, Mary ^a   Uyeki, Timothy M ^a   Bausch, Daniel ^b   Ksiazek, Thomas ^b   Thomas, William ^d   Alterson, Harold ^c   Smith, Jonathan ^c   Ambrosino, Donna M ^d   Anderson, Larry J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c AlphaVax Inc   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; IMMUNOGLOBULIN G; NUCLEOCAPSID PROTEIN; RECOMBINANT PROTEIN; RNA; SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEVERE ACUTE RESPIRATORY SYNDROME;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MEMBRANE GLYCOPROTEINS; NUCLEOCAPSID PROTEINS; RECOMBINANT PROTEINS; SARS VIRUS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS;

EID: 34147134992     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00351-06     Document Type: Article

References (23)

1. Babcock, G. J., D. J. Esshaki, W. D. Thomas, Jr., and D. M. Ambrosino. 2004. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 78:4552-4560.
2. Chang, M. S., Y. T. Lu, S. T. Ho, C. C. Wu, T. Y. Wei, C. J. Chen, Y. T. Hsu, P. C. Chu, C. H. Chen, J. M. Chu, Y. L. Jan, C. C. Hung, C. C. Fan, and Y. C. Yang. 2004. Antibody detection of SARS-CoV spike and nucleocapsid protein. Biochem. Biophys. Res. Commun. 314:931-936.
3. Drosten, C., S. Gunther, W. Preiser, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. Fouchier, A. Berger, A. M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J. C. Mannguerra, S. Muller, V. Rickerts, M. Stunner, S. Vieth, H. D. Klenk, A. D. Osterhaus, H. Schmitz, and H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
4. He, Z., Q. Dong, H. Zhuang, S. Song, G. Peng, G. Luo, and D. E. Dwyer. 2004. Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS. Clin. Diagn. Lab. Immunol. 11:792-794.
5. Huang, L. R., C. M. Chiu, S. H. Yeh, W. H. Huang, P. R. Hsueh, W. Z. Yang, J. Y. Yang, I. J. Su, S. C. Chang, and P. J. Chen. 2004. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J. Med. Virol. 73:338-346.
6. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E. Ling, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J. Bellini, L. J. Anderson, and SARS Working Group. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
7. Lee, J. S., P. Pushko, M. D. Parker, M. T. Dertzbaugh, L. A. Smith, and J. F. Smith. 2001. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect. Immun. 69:5709-5715.
8. Li, S., L. Lin, H. Wang, J. Yin, Y. Ren, Z. Zhao, J. Wen, C. Zhou, X. Zhang, X. Li, J. Wang, Z. Zhou, J. Liu, J. Shao, T. Lei, J. Fang, N. Xu, and S. Liu. 2003. The epitope study on the SARS-CoV nucleocapsid protein. Genomics Proteomics Bioinformatics 1:198-206.
9. Liang, G., Q. Chen, J. Xu, Y. Lin, W. Lim, J. S. Peiris, L. J. Anderson, L. Ruan, H. Li, B. Kan, B. Di, P. Cheng, K. H. Chan, D. D. Erdman, S. Gu, X. Yan, W. Liang, D. Zhou, L. Haynes, S. Duan, X. Zhang, H. Zheng, Y. Gao, S. Tong, D. Li, L. Fang, P. Qin, W. Xu, and SARS Diagnosis Working Group. 2004. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 10:1774-1781.
10. Liu, G., S. Hu, Y. Hu, P. Chen, J. Yin, J. Wen, J. Wang, L. Lin, J. Lin, B. You, Y. Yin, S. Li, H. Wang, Y. Ren, J. Ji, X. Zhao, Y. Sun, X. Zhang, J. Fang, J. Wang, S. Liu, J. Yu, H. Zhu, and H. Yang. 2003. The C-terminal portion of the nucleocapsid protein demonstrates SARS-CoV antigenicity. Genomics Proteomics Bioinformatics 1:193-197.
11. Liu, W., A. Fontanet, P. H. Zhang, L. Zhan, Z. T. Xin, L. Baril, F. Tang, H. Lv, and W. C. Cao. 2006. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome (SARS). J. Infect. Dis. 193:792-795.
12. Liu, X., Y. Shi, P. Li, L. Li, Y. Yi, Q. Ma, and C. Cao. 2004. Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clin. Diagn. Lab. Immunol. 11:227-228.
13. Maache, M., F. Komurian-Pradel, A. Rajoharison, M. Perret, J.-L. Berland, S. Pouzol, A. Bagnaud, B. Duverger, J. Xu, A. Osuna, and G. Paranhos-Baccalà. 2006. False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based Western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV. Clin. Vaccine Immunol. 13:409-414.
14. Narayanan, K., K. H. Kim, and S. Makino. 2003. Characterization of N protein self-association in coronavirus ribonucleoprotein complexes. Virus Res. 98:131-140.
15. Ndifuna, A., A. K. Waters, M. Zhou, and E. W. Collisson. 1998. Recombinant nucleocapsid protein is potentially an inexpensive, effective serodiagnostic reagent for infectious bronchitis virus. J. Virol. Methods 70:37-44.
16. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls, W. K. Yee, W. W. Yan, M. T. Cheung, V. C. Cheng, K. H. Chan, D. N. Tsang, R. W. Yung, T. K. Ng, K. Y. Yuen, and SARS Study Group. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
17. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
18. Riley, S., C. Fraser, C. A. Donnelly, A. C. Ghani, L. J. Abu-Raddad, A. J. Hedley, G. M. Leung, L. M. Ho, T. H. Lam, T. Q. Thach, P. Chau, K. P. Chan, S. V. Lo, P. Y. Leung, T. Tsang, W. Ho, K. H. Lee, E. M. Lau, N. M. Ferguson, and R. M. Anderson. 2003. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300:1951-1966.
19. Temperton, N. J., P. K. Chan, G. Simmons, M. C. Zambon, R. S. Tedder, Y. Takeuchi, and R. A. Weiss. 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11:411-416.
20. U.S. Department of Health and Human Services. 2005. Code of Federal Regulations 46.101(b)(4).
21. Woo, P. C. Y., S. K. P. Lau, B. H. L. Wong, K.-H. Chan, C.-M. Chu, H.-W. Tsoi, Y. Huang, J. S. Malik Peiris, and K.-Y. Yuen. 2004. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin. Diagn. Lab. Immunol. 11:665-668.
22. Woo, P. C., S. K. Lau, B. H. Wong, K. H. Chan, W. T. Hui, G. S. Kwan, J. S. Peiris, R. B. Couch, and K. Y. Yuen. 2004. False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J. Clin. Microbiol. 42:5885-5888.
23. Zhou, T., H. Wang, D. Luo, T. Rowe, Z. Wang, R. J. Hogan, S. Qui, R. J. Bunzel, G. Huang, V. Mishra, T. G. Voss, R. Kimberly, and M. Luo. 2004. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J. Virol. 78:7217-7226.